During Friday’s current trade, Autohome Inc (ADR) (NYSE:ATHM)’s shares decline -3.68% to $48.14.
Autohome Inc. (ATHM) the leading online destination for automobile consumers in China, recently declared that Mr. Xiang Li will step down from the position of President of the Company while remaining as a director on the board of directors, effective right away.
Autohome Inc. operates as an online destination for automobile consumers in the People’s Republic of China. The company, through its Websites, autohome.com.cn and che168.com, delivers independent and interactive content to automobile buyers and owners, counting professionally produced content that comprises automobile-related articles and reviews, pricing trends in various markets, and photos and video clips; automobile library, which comprises a range of specifications covering performance levels, dimensions, powertrains, vehicle bodies, interiors, safety, entertainment systems, and other unique features, in addition to manufacturer’s suggested retail prices; new and used automobile listings, and promotional information; and user forums and user generated content. Autohome Inc. also offers advertising services for automakers and dealers; dealer subscription services that allow dealers to market their inventory and services through its Websites; used automobile listings services, which allow used automobile dealers and individuals to market their automobiles for sale on its Websites; and automobile dealer subscription services that enable dealers to establish and maintain online showrooms of automobiles with pricing and promotional information on autohome.com.cn.
DSW Inc. (NYSE:DSW)‘s shares gain 0.35% to $34.74, during the current trading session Friday’s, hitting its highest level.
DSW Inc. (DSW) will be giving back to the community through its Shoe Lovers Care Leave Your Mark program for the fourth time since 2013. Shoe Lovers Care Leave Your Mark enables DSW associates to nominate non-profits that make an impression on their lives for a chance to receive a $75,000 donation from DSW.
DSW associates nationwide were encouraged to nominate a local or national cause dear to their hearts. After internally reviewing the applications, DSW has selected 5 local and 3 national finalists to compete for the $75,000 donation. The finalists are: Association for Women in Science – Massachusetts Chapter; Brother Wolf Animal Rescue; Colon Cancer Alliance; Darkness to Light; Fisher House Foundation; The Foundation for New Education Initiatives, Inc.; Village Family Services; and YWCA Columbus.
DSW Inc., together with its auxiliaries, operates as a branded footwear and accessories retailer in the United States. The company operates through two segments, DSW and Associated Business Group. It offers dresses, casual and athletic footwear, and accessories under various brands for women, men, and kids. The company also provides handbags, hosiery, jewelry, and other accessories.
In a mid-morning trade, Axovant Sciences Ltd (NYSE:AXON)‘s shares plunge -1.19% to $19.03.
Axovant Sciences Ltd. (AXON), a clinical-stage biopharmaceutical company, recently declared the completion of its initial public offering of 24,150,000 common shares, counting 3,150,000 common shares sold following the full exercise of the underwriters’ formerly granted option to purchase additional common shares. All of the common shares were offered by Axovant at a public offering price of $15.00 per share. The common shares of Axovant began trading under the ticker symbol “AXON” on June 11, 2015. The gross proceeds to Axovant from this offering, prior to deducting underwriting discounts and commissions and estimated offering expenses payable by Axovant, were about $362 million.
Jefferies LLC, Evercore Group L.L.C. and RBC Capital Markets LLC acted as joint book-running managers for the offering. JMP Securities LLC acted as lead manager, and Robert W. Baird & Co. Incorporated acted as co-manager for the offering.
Axovant Sciences Ltd., a clinical-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics for the treatment of neurodegenerative disorders. It develops RVT-101, a product candidate that plans to commence a Phase III pivotal program for the treatment of Alzheimer’s disease and other forms of dementia.
StemCells Inc (NASDAQ:STEM), during its Friday’s current trading session -2.06% loss and closed at $0.666.
StemCells, Inc. (STEM), a world leader in the research and development of cell-based therapeutics for the treatment of central nervous system diseases and disorders, declared recently that Health Canada has authorized the Company to expand its Phase II clinical trial for chronic cervical spinal cord injury into Canada. The Pathway Study(TM) is designed to assess the efficacy of the Company’s proprietary HuCNS-SC(R) platform technology (purified human neural stem cells) for the treatment of cervical spinal cord injury with the primary efficacy outcome being the change in motor strength of the various muscle groups in the upper extremities innervated by the cervical spinal cord.
StemCells, Inc., a biopharmaceutical company, researches, develops, and commercializes cell-based therapeutics and related technologies for stem cell-based research and drug discovery and development. It engages in clinical development of its platform technology, HuCNS-SC, a purified human neural stem cells used as a potential treatment for disorders of the central nervous system.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
